Back to Search Start Over

Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma

Authors :
Young Joo Park
Yuh-Seog Jung
Su Jin Kim
Jae Hoon Moon
Do Joon Park
June Young Choi
Chang Hwan Ryu
Eun Jae Chung
Jeong Hun Hah
Ji Ye Lee
Yu-Mi Lee
You Jin Lee
Kyu Eun Lee
Eun Kyung Lee
Chang Yoon Lee
Woo Jin Jeong
Yul Hwangbo
Junsun Ryu
Min Joo Kim
Sun Wook Cho
Ji Hoon Kim
Yeo Koon Kim
Hyeong Won Yu
Source :
The Journal of Clinical Endocrinology & Metabolism. 106:724-735
Publication Year :
2020
Publisher :
The Endocrine Society, 2020.

Abstract

Context The long-term quality of life (QoL) in patients with low-risk papillary thyroid microcarcinoma (PTMC) underwent active surveillance (AS) and immediate surgery is unclear. Objective The aim of this study was to investigate the effect of initial treatment choice on 2-year QoL in patients with low-risk PTMC Design, Setting, and Participants We analyzed 2652 QoL surveys from 1055 subjects enrolled in ongoing multicenter prospective cohort study on active surveillance of PTMC, in which the median follow-up duration was 24.4 months. Major Outcome Measure We evaluated QoL of patients with low-risk PTMC according to their treatment modality using generalized estimating equation. Results Six hundred and seventy-four subjects (male = 161; mean age = 48.8 ± 11.9 years) with low-risk PTMC chose AS while 381 subjects (male = 75; mean age = 45.7 ± 10.4 years) chose immediate surgery, including lobectomy/isthmusectomy (L/I) and total thyroidectomy (TT). Among the 817 subjects who completed baseline QoL surveys, 2-year QoL was good in order of AS (n = 500), L/I (n = 238), and TT (n = 79) groups after adjustment for age, sex, baseline tumor size, and baseline QoL scores. Among the 101 subjects who changed their treatment from AS to surgery during the follow-up period, 35 subjects who changed treatment due to disease progression had better QoL than 66 subjects who had no disease progression. Conclusions This study identified QoL as a major issue in choosing an initial treatment of low-risk PTMC and highlighted the possibility of using AS as the primary treatment.

Details

ISSN :
19457197 and 0021972X
Volume :
106
Database :
OpenAIRE
Journal :
The Journal of Clinical Endocrinology & Metabolism
Accession number :
edsair.doi.dedup.....702163a6d69c0b0f5f9e9cc2aceffc1b